China NT Pharma Group Company Limited Announces Acquisition and Listing

China NT Pharma Group Company Limited, a pharmaceutical company in Hong Kong, has announced that it will acquire 100% of the issued shares in the Target Companies through a conditional agreement. The acquisition is valued at RMB116,219,960 (approximately HKD123,638,256) and will be satisfied by the allotment and issue of Consideration Shares. The listing of the Consideration Shares on the Hong Kong Stock Exchange is pending approval from the Stock Exchange and the shareholders.

Key Takeaways:

• China NT Pharma Group Company Limited has conditionally agreed to purchase 100% of the issued shares in the Target Companies for RMB116,219,960 (approximately HKD123,638,256).
• The consideration for the acquisition will be satisfied by the allotment and issue of Consideration Shares.
• The acquisition constitutes a major transaction under the Hong Kong Listing Rules and is subject to the reporting, announcement, circular, and Shareholders' approval requirements.
• The sale and purchase agreement is expected to be approved by shareholders at an extraordinary general meeting (EGM).
• The EGM will consider and approve the grant of a Specific Mandate for the allotment and issue of the Consideration Shares.
• The acquisition will result in the Enlarged Group, which will include the Target Companies, and a circular containing financial information of the PRC Operating Company and the unaudited pro forma financial information of the Enlarged Group will be despatched to shareholders.

Statistics:

• RMB116,219,960 (approximately HKD123,638,256) is the consideration for the acquisition.
• The acquisition constitutes a major transaction under the Hong Kong Listing Rules, which requires reporting, announcement, circular, and Shareholders' approval.

Sources:

• Announcement by China NT Pharma Group Company Limited dated 28 April 2025

Referenced in: https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0428/2025042804093.pdf